One-Year Comparative Effectiveness of Upadacitinib vs Tofacitinib for Ulcerative Colitis: A Multicenter Cohort Study

被引：8

作者：

Dalal, Rahul S. ^{[1
]}

Kallumkal, Govind ^{[2
]}

Cabral, Heidy J. ^{[1
]}

Barnes, Edward L. ^{[3
]}

Allegretti, Jessica R. ^{[1
]}

机构：

[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Gastroenterol Hepatol & Endoscopy, Boston, MA 02115 USA

[2] Univ N Carolina, Dept Med, Chapel Hill, NC USA

[3] Univ N Carolina, Dept Med, Div Gastroenterol, Chapel Hill, NC USA

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 08期

关键词：

small molecule; Janus kinase inhibitor; inflammatory bowel disease; remission; biologic; MAINTENANCE THERAPY; INDUCTION;

D O I：

10.14309/ajg.0000000000002746

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

INTRODUCTION: The comparative effectiveness of upadacitinib and tofacitinib for ulcerative colitis (UC) is poorly understood. METHODS: In this retrospective cohort study, we compared steroid-free clinical remission (SFCR) and endoscopic response/remission at 52 weeks among adults initiating upadacitinib or tofacitinib for UC. RESULTS: A total of 155 patients initiated upadacitinib (n = 81; 30% prior tofacitinib exposure) or tofacitinib (n = 74; 0% prior upadacitinib exposure). After inverse probability of treatment-weighted logistic regression, upadacitinib was associated with significantly higher odds of SFCR (odds ratio 3.01, 95% confidence interval 1.39-6.55) vs tofacitinib. There were no differences for endoscopic response/remission. DISCUSSION: Upadacitinib was more effective at achieving SFCR in UC at 52 weeks vs tofacitinib.

引用

页码：1628 / 1631

页数：4

共 50 条

[21] Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study
Gilmore, Robert
Fernandes, Richard
Hartley, Imogen
Arzivian, Arteen
Leong, Rupert
Andrew, Bridgette
Vasudevan, Abhinav
Greeve, Tessa
Moore, Gregory Thomas
Kim, Steven
Lightowler, Daniel
Singh, Abhey
Mahy, Gillian
Mithanthaya, Aditya
Venugopaul, Kannan
Han, Sangwoo
Bryant, Robert
West, Jack
Segal, Jonathan
Christensen, Britt
Corte, Crispin
Ding, Nik
An, Yoon-Kyo
Begun, Jakob
INTESTINAL RESEARCH, 2024,
[22] 1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure
Dalal, Rahul S.
Sharma, Puza P.
Bains, Kanwal
Pruce, Jordan C.
Allegretti, Jessica R.
INFLAMMATORY BOWEL DISEASES, 2024, 30 (03) : 395 - 401
[23] Clinical and Endoscopic Outcomes After Upadacitinib Induction for Ulcerative Colitis: A Multicenter Retrospective Cohort Study
Dalal, Rahul S.
Kallumkal, Govind
Cabral, Heidy J.
Bachour, Salam
Barnes, Edward L.
Allegretti, Jessica R.
INFLAMMATORY BOWEL DISEASES, 2023, 30 (07) : 1207 - 1210
[24] Comparative effectiveness and safety of upadacitinib, tofacitinib, and filgotinib in patients with Ulcerative Colitis: analysis of whole and propensity score-matched data
Bertin, L.
Scarabello, D.
Zingone, F.
Savarino, E., V
Barberio, B.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1294 - i1295
[25] REAL-WORLD COMPARATIVE EFFECTIVENESS OF UPADACITINIB VS USTEKINUMAB FOR ULCERATIVE COLITIS AT 8-12 WEEKS
Dalal, Rahul S.
Radcliffe, Marlana
Sninsky, Jared A.
Bachour, Salam
Barnes, Edward L.
Marcus, Jenna
Allegretti, Jessica R.
GASTROENTEROLOGY, 2023, 164 (06) : S651 - S652
[26] COMPARATIVE EFFICACY OF USAT VS CBT: ONE-YEAR MORTALITY AND BLEEDING EVENTS IN A MULTICENTER STUDY
Amaechi, Eze
Ndukauba, Chinonso
Mazhude, Tawana
Hernandez, Aurelia
Cuello Ramirez, Alejandrina
Gogolauri, Saba
Omonuwa, Kennedy
CRITICAL CARE MEDICINE, 2025, 53 (01)
[27] Upadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An International Multicenter Study
Yerushalmy-Feler, Anat
Spencer, Elizabeth A.
Dolinger, Michael T.
Suskind, David L.
Mitrova, Katarina
Hradsky, Ondrej
Conrad, Maire A.
Kelsen, Judith R.
Uhlig, Holm H.
Tzivinikos, Christos
Ancona, Silvana
Wlazlo, Magdalena
Hackl, Lukas
Shouval, Dror S.
Bramuzzo, Matteo
Urlep, Darja
Olbjorn, Christine
D'Arcangelo, Giulia
Pujol-Muncunill, Gemma
Yogev, Dotan
Kang, Ben
Gasparetto, Marco
Rungo, Christine
Kolho, Kaija-Leena
Hojsak, Iva
Norsa, Lorenzo
Rinawi, Firas
Sansotta, Naire
Magen Rimon, Ramit
Granot, Maya
Scarallo, Luca
Trindade, Eunice
Velasco Rodriguez-Belvis, Marta
Turner, Dan
Cohen, Shlomi
JOURNAL OF CROHNS & COLITIS, 2024,
[28] Upadacitinib for induction of remission in pediatric Ulcerative Colitis: An international multicenter study
Yerushalmy-Feler, A.
Spencer, E. A.
Dolinger, M. T.
Suskind, D. L.
Mitrova, K.
Hradsky, O.
Conrad, M. A.
Kelsen, J. R.
Uhlig, H. H.
Tzivinikos, C.
Ancona, S.
Wlazlo, M.
Hackl, L.
Shouval, D. S.
Bramuzzo, M.
Urlep, D.
Olbjorn, C.
D'Arcangelo, G.
Pujol-Muncunill, G.
Yogev, D.
Kang, B.
Gasparetto, M.
Rungo, C.
Kolho, K. L.
Hojsak, I
Norsa, L.
Rinawi, F.
Sansotta, N.
Rimon, R. Magen
Granot, M.
Scarallo, L.
Trindade, E.
Rodriguez-Belvis, M. Velasco
Turner, D.
Cohen, S.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i182 - i183
[29] Effectiveness of upadacitinib in patients with Ulcerative Colitis: a real-life, multicenter, Italian report
Teani, I.
Bevilacqua, N.
Gabbiadini, R.
Bezzio, C.
Ferronato, A.
Saibeni, S.
Armuzzi, A.
Comberlato, M.
Desideri, F.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1045 - I1046
[30] EFFECTIVENESS OF UPADACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: A REAL-LIFE, MULTICENTER, ITALIAN REPORT
Teani, I
Bevilacqua, N.
Gabbiadini, R.
Bezzio, C.
Ferronato, A.
Saibeni, S.
Armuzzi, A.
Comberlato, M.
Desideri, F.
DIGESTIVE AND LIVER DISEASE, 2024, 56 : S244 - S245

← 1 2 3 4 5 →